Harvard Apparatus Regenerative Technology, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

Three Months Ended · Six Months Ended
	June 30,		June 30,
	2026	2025	2026	2025
Product revenue	$414	$317	$640	$362
Operating expenses:
Cost of sales	391	302	597	335
Research and development	948	697	1,511	1,298
Sales and marketing	16	—	34	10
General and administrative	751	1,151	1,796	2,222
Total operating expenses	2,106	2,150	3,938	3,865
Operating loss	(1,692)	(1,833)	(3,298)	(3,503)
Other (expense) income, net:
Interest income	—	7	2	20
Interest expense	(8)	(3)	(10)	(5)
Other income	5	6	10	6
Other (expense) income, net	(3)	10	2	21
Net loss	$(1,695)	$(1,823)	$(3,296)	$(3,482)
Basic and diluted net loss per share	$(0.10)	$(0.11)	$(0.19)	$(0.22)
Weighted average common shares outstanding, basic and diluted	17,580,744	15,918,979	17,580,744	15,918,979
Comprehensive loss:
Net loss	$(1,695)	$(1,823)	$(3,296)	$(3,482)
Foreign currency translation adjustments	1	(1)	5	(1)
Comprehensive loss	$(1,694)	$(1,824)	$(3,291)	$(3,483)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.